Hal W. Hirte, MD, FRCP(C)
Dr. Hirte has been active as a principal investigator and co-investigator in phase I, II and III trials for gynecological malignancies. His interests are focussed on the assessment of novel molecular targeted therapies, including signalling inhibitors and anti-angiogenic therapies, and the determination of relevant clinical and molecular endpoint in studies using such agents. He heads the Investigational New Drug Fellowship Programme at the Hamilton Regional Cancer, and is the principal investigator at the centre, for the Princess Margaret-Hamilton-London (PHL) consortium for phase II drug development. He is a member of the NCIC-CTG Investigational New Drug Committee executive, as well as the Gynecologic Oncology Disease Site executive, and chairs the NCIC-CTG Angiogenesis Working Group. In addition, he sits on grants review panels for the National Cancer Institute of Canada and the Cancer Research Society.